Pasanen M - Search Results

1

Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes.

Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO. Asikainen A, et al. Among authors: pasanen m. Toxicol In Vitro. 2003 Aug;17(4):449-55. doi: 10.1016/s0887-2333(03)00065-1. Toxicol In Vitro. 2003. PMID: 12849728

2

Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations.

Pelkonen O, Turpeinen M, Hakkola J, Abass K, Pasanen M, Raunio H, Vähäkangas K. Pelkonen O, et al. Among authors: pasanen m. Toxicol In Vitro. 2013 Aug;27(5):1578-83. doi: 10.1016/j.tiv.2012.06.002. Epub 2012 Jun 19. Toxicol In Vitro. 2013. PMID: 22728233

3

Lack of association between CYP2A5 induction and apoptosis in mouse primary hepatocytes.

Tetri S, Ruhanen M, Viitala P, Pelkonen O, Pasanen M, Raunio H. Tetri S, et al. Among authors: pasanen m. Biochem Pharmacol. 2002 Feb 1;63(3):429-35. doi: 10.1016/s0006-2952(01)00909-1. Biochem Pharmacol. 2002. PMID: 11853694

4

Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.

Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M. Sotaniemi EA, et al. Among authors: pasanen m. Pharmacol Toxicol. 2002 Mar;90(3):155-60. doi: 10.1034/j.1600-0773.2002.900308.x. Pharmacol Toxicol. 2002. PMID: 12071338 Clinical Trial.

5

In silico prediction of the site of oxidation by cytochrome P450 3A4 that leads to the formation of the toxic metabolites of pyrrolizidine alkaloids.

Fashe MM, Juvonen RO, Petsalo A, Vepsäläinen J, Pasanen M, Rahnasto-Rilla M. Fashe MM, et al. Among authors: pasanen m. Chem Res Toxicol. 2015 Apr 20;28(4):702-10. doi: 10.1021/tx500478q. Epub 2015 Feb 17. Chem Res Toxicol. 2015. PMID: 25651456

6

Identification of a new reactive metabolite of pyrrolizidine alkaloid retrorsine: (3H-pyrrolizin-7-yl)methanol.

Fashe MM, Juvonen RO, Petsalo A, Rahnasto-Rilla M, Auriola S, Soininen P, Vepsäläinen J, Pasanen M. Fashe MM, et al. Among authors: pasanen m. Chem Res Toxicol. 2014 Nov 17;27(11):1950-7. doi: 10.1021/tx5002964. Epub 2014 Oct 21. Chem Res Toxicol. 2014. PMID: 25295702

7

The unique characteristics of the placental transcriptome and the hormonal metabolism enzymes in placenta.

Storvik M, Huuskonen P, Pehkonen P, Pasanen M. Storvik M, et al. Among authors: pasanen m. Reprod Toxicol. 2014 Aug;47:9-14. doi: 10.1016/j.reprotox.2014.04.010. Epub 2014 May 9. Reprod Toxicol. 2014. PMID: 24814680

8

The effects of aflatoxin B1 on transporters and steroid metabolizing enzymes in JEG-3 cells.

Huuskonen P, Myllynen P, Storvik M, Pasanen M. Huuskonen P, et al. Among authors: pasanen m. Toxicol Lett. 2013 Apr 26;218(3):200-6. doi: 10.1016/j.toxlet.2013.01.015. Epub 2013 Feb 10. Toxicol Lett. 2013. PMID: 23402939

9

2'-Deoxyguanosine as a surrogate trapping agent for DNA reactive drug metabolites.

Häkkinen MR, Laine JE, Juvonen RO, Auriola S, Häyrinen J, Pasanen M. Häkkinen MR, et al. Among authors: pasanen m. Toxicol Lett. 2011 Nov 10;207(1):34-41. doi: 10.1016/j.toxlet.2011.08.020. Epub 2011 Sep 2. Toxicol Lett. 2011. PMID: 21907773

10

Aflatoxin B1--a potential endocrine disruptor--up-regulates CYP19A1 in JEG-3 cells.

Storvik M, Huuskonen P, Kyllönen T, Lehtonen S, El-Nezami H, Auriola S, Pasanen M. Storvik M, et al. Among authors: pasanen m. Toxicol Lett. 2011 May 10;202(3):161-7. doi: 10.1016/j.toxlet.2011.01.028. Epub 2011 Feb 4. Toxicol Lett. 2011. PMID: 21296134

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results